Injectable Hydrogel Depot Sustains Semaglutide Release for Six Weeks, Improving Glucose and Weight Control
Background
Current subcutaneous delivery systems for therapeutic peptides, such as GLP-1 receptor agonists, frequently suffer from an initial burst release followed by inadequate sustained exposure. This pharmacokinetic variability limits depot lifetime and necessitates frequent dosing, impacting patient adherence and treatment efficacy for chronic conditions like Type 2 Diabetes and obesity. Engineering long-acting depots that maintain consistent therapeutic levels is a critical unmet need to improve patient convenience and clinical outcomes.
Study Design
Researchers engineered a dynamic, injectable hydrogel depot for long-acting peptide delivery, using semaglutide as a model cargo. They developed a modular framework focusing on depot mechanics, cargo complexation (hydrophobic/ion-mediated), and oxidative stabilization with antioxidants. Depot performance was assessed via rheology and in vitro release assays. In vivo studies in rodents compared a single hydrogel administration of semaglutide against daily subcutaneous dosing, evaluating pharmacokinetic profiles, glucose control, weight regulation, and pancreatic islet content over six weeks.
Results
Optimized hydrogel formulations successfully sustained semaglutide exposure for over six weeks from a single administration in rodents. This extended release significantly reduced pharmacokinetic variability, demonstrating a two-fold reduction in peak-to-trough exposure compared to daily dosing. Crucially, the total bioavailability of semaglutide from the hydrogel depot was comparable to that achieved with daily injections, indicating efficient drug delivery.
The sustained release of semaglutide from the hydrogel depot led to improved glucose control, enhanced weight regulation, and preserved pancreatic islet content in the treated animals. These results highlight the hydrogel's ability to maintain consistent therapeutic levels of the GLP-1 receptor agonist over an extended period, translating into superior pharmacodynamic outcomes. The integrated formulation framework effectively managed cargo-matrix and cargo-excipient interactions across burst, diffusion, and erosion phases.
Key Findings
- Hydrogel depot sustained semaglutide exposure for over six weeks from a single administration.
- Achieved a two-fold reduction in peak-to-trough semaglutide exposure compared to daily dosing.
- Demonstrated comparable total bioavailability of semaglutide from the depot vs. daily injections.
- Improved glucose control and weight regulation in rodents receiving the long-acting semaglutide.
- Preserved pancreatic islet content, indicating better metabolic health outcomes.
Why It Matters
This research presents a significant advancement for patients requiring long-term peptide therapies, particularly those for Type 2 Diabetes and obesity. A single hydrogel injection could replace daily or weekly semaglutide doses, potentially enabling quarterly administration in humans. This dramatic reduction in injection frequency would vastly improve patient adherence, convenience, and overall quality of life, addressing a major barrier in chronic disease management. The structured formulation framework offers a generalizable approach for developing similar long-acting depots for other therapeutic peptides, accelerating the translation of novel compounds into practical, patient-friendly protocols. This could redefine how peptides are delivered, moving towards highly infrequent, yet consistently effective, dosing regimens.
semaglutide
hydrogel
long-acting
peptide-delivery
type-2-diabetes
obesity